Several other research analysts have also recently weighed in on the stock. HC Wainwright set a $8.00 price objective on shares of AzurRx BioPharma and gave the stock a buy rating in a research report on Friday, November 2nd. ValuEngine upgraded shares of AzurRx BioPharma from a hold rating to a buy rating in a research report on Thursday, November 1st. Finally, CIBC assumed coverage on shares of AzurRx BioPharma in a research report on Wednesday, October 17th. They issued an outperform rating and a $6.00 price objective on the stock.
AZRX stock opened at $1.76 on Wednesday. AzurRx BioPharma has a 1-year low of $1.69 and a 1-year high of $4.08.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.